SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is under pressure as traders worry that post-election calls for tighter AI regulation could slow data-center construction and weaken demand for AI-related memory chips. The community is split between those who see the selloff as an overreaction with memory demand intact and those warning that slower AI spending or a peak in the memory cycle could bring further declines.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is under pressure amid fears that the post-election political landscape could bring tighter AI regulation and data-center permitting delays, slowing infrastructure spending; concerns about the sustainability of AI capex and circular financing add to the debate. Traders are split between seeing a broader risk to chip demand and treating the selloff as an overreaction, arguing that projects and GPU demand could shift elsewhere.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is selling off with memory and AI-linked chip stocks as Democratic gains in Congress fuel trader concerns that tighter AI and data-center rules could slow future infrastructure buildouts. Bulls call the move an overreaction and point to continued memory demand, while bears warn of prolonged weakness in the AI trade and memorys cyclical risks.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snaps quarterly report missed revenue and daily-active-user expectations, while advertising growth remained sluggish, prompting a sharp post-earnings selloff and criticism of management. Traders are split: bears focus on weak user and ad trends and the shift toward MAUs as a reported metric, while bulls point to improved profitability, cash flow, subscriptions, and the companys outlook.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsiuss Q3 results beat expectations, with growth led by Alani Nu and international sales, but traders are debating whether that strength can offset weakness in the core Celsius brand and compressed margins. Reactions are broadly positive on the sales beat, tempered by concerns about profitability and the durability of growth.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is drawing attention amid a sharp semiconductor selloff, with traders debating whether fears of tighter AI and data-center regulation after the midterm results are justified; weak reactions to chip-company earnings are also cited. Some see the decline as an overdone, oversold move and are buying for a bounce, while others expect more downside and warn that the funds 3x leverage magnifies volatility.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Reported Lundbeck takeover interest has fueled heavy speculation about a possible bid or bidding war, though Xeris has said it is not for sale and traders disagree on whether a deal is likely. The debate is reinforced by optimism about Recorlevs growth and XP-8121s Phase 3 prospects, alongside skepticism about the long development timeline.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Q3 results showing strong commercial growth and expanding gross margins have drawn attention, though Iovance reaffirmed rather than raised its full-year outlook. Traders praise the improving business trajectory, while others point to the muted share-price reaction and lingering uncertainty around the NSCLC data and filing timeline.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unitys quarterly results beat expectations, marking its first GAAP-profitable quarter, with upbeat guidance and strong Vector advertising growth driving attention. Traders largely celebrated the results as a potential business inflection, while some questioned whether the rally was excessive and how sustainable the growth will be.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Jobys quarterly revenue beat and raised outlook, alongside progress in FAA certification testing and aircraft production, are drawing attention. Bulls view the update and expanding defense work as signs of execution, while skeptics question how quickly certification and commercial operations can advance amid ongoing cash burn.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Did Kyverna Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Did Kyverna Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? Did Kyverna Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?PR NewswireNEW YORK, Oct. 22, 2026 Shareholders are encouraged to contact the firm to discuss their rights and options at no...

KYTX Stock Reverses Gains After One-Year Cell Therapy Trial Data — But CEO Says Disease Burden Justifies A Premium Price

Equity

Chief executive Warner Biddle said the therapy’s durability “exceeded even our expectations.” 



Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?

Key PointsKyverna Therapeutics is a clinical-stage biopharmaceutical firm advancing cell therapies for autoimmune diseases...

Kyverna Therapeutics Names Greg Martini CFO

(RTTNews) - Kyverna Therapeutics, Inc. (KYTX), Monday announced the appointment of Greg Martini as Chief Financial Officer, effective May 18...

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) have received an average rating of 'Moderate Buy' from the five research firms that are covering the company, Marketbeat Ratings...

Kyverna Therapeutics (KYTX) to Release Earnings on Tuesday

Kyverna Therapeutics (NASDAQ:KYTX) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at...

AIGH Capital Management LLC Acquires Shares of 1,500,000 Kyverna Therapeutics, Inc. $KYTX

AIGH Capital Management LLC purchased a new stake in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 1,500,000 shares of the company's stock, valued at approximately...

Kyverna Therapeutics Showcases miv-cel Data in SPS, gMG; CEO Eyes First Autoimmune CAR-T BLA

Kyverna Therapeutics (NASDAQ:KYTX) highlighted new clinical data for its CD19-directed autologous CAR T-cell therapy mivocabtagene autoleucel (miv-cel), formerly KYV-101, during an American Academy of Neurology (AAN) conference call focused on stiff person syndrome (SPS) and generalized myasthenia g...

Peapod Lane Capital LLC Decreases Holdings in Kyverna Therapeutics, Inc. $KYTX

Peapod Lane Capital LLC decreased its position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) by 42.3% during the 4th quarter, according to its most recent disclosure with the SEC. The...

Kyverna Therapeutics' (KYTX) "Buy" Rating Reiterated at HC Wainwright

HC Wainwright restated a "buy" rating and set a $20.00 price target on shares of Kyverna Therapeutics in a research note on Thursday...

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

Bearish Sentiment

<ul class="summary-bullets"><li>Miv-cel is a one-dose treatment made from a patient’s own immune cells and designed to reset the attack on the nervous system.</li><li>In the 26-patient stiff person syndrome study, walking speed improved by a median 49% at one year.</li><li>Kyverna said it will fold the one-year stiff person syndrome results into a rolling application for U.S. approval, still slated to finish in the fourth quarter of 2026.</li></ul><p>Shares of Kyverna Therapeutics (KYTX) fell on Thursday even after the company reported that a one-time cell therapy kept helping patients with stiff person syndrome (SPS) and generalized myasthenia gravis a full year later.</p><p>Investors had already priced in much of the good news after earlier trial readouts. Thursday’s update confirmed that benefits lasted, but did not deliver a surprise.</p><p>Kyverna opened near $7.80, up more than 10%, then reversed, trading as low as about $6.68, or 5.5% lower than Wednesday’s close.</p><h2 class="st-heading-2">What The Data Showed</h2><p>Miv-cel is a one-dose treatment made from a patient’s own immune cells and designed to reset the attack on the nervous system. In the 26-patient stiff person syndrome study, walking speed improved by a median 49% at one year. Nearly all patients who had gained ground by week 16 still held that gain. Most no longer needed long-term immune-suppressing drugs, and two-thirds of those who once used a walking aid no longer needed one.</p><p>Safety stayed clean: No severe cytokine storms or the most serious treatment-related brain side effects. Five patients had expected low white-cell counts; all were manageable, and none had serious infections, the company said.</p><p>A smaller myasthenia gravis study of seven patients showed the same theme. All improved on standard symptom scores by six months, and those followed for a year or more kept the benefit. Most remained off chronic medicines.</p><h2 class="st-heading-2">What Executives Emphasized</h2><p>Chief executive Warner Biddle said the durability “exceeded even our expectations.”</p><p>Biddle said SPS is expensive and devastating: treating one patient can cost $700,000 to more than $1.5 million over three years, and fewer than 1 in 5 patients are still working four years after diagnosis. That burden, he said, supports charging more than the $500,000 to $600,000 now paid for similar cancer cell therapies. About 6,000 people in the U.S. have been diagnosed. At launch, Kyverna plans to start with the 2,000 to 2,500 patients who are not getting enough help from current off-label drugs, many of them treated at about 10 major academic hospitals.</p><h2 class="st-heading-2">What Comes Next</h2><p>Kyverna said it will fold the one-year stiff person syndrome results into a rolling application for U.S. approval, still slated to finish in the fourth quarter of 2026. Fuller data will be presented at medical meetings later this month and in October. A larger myasthenia gravis trial is expected to finish enrolling around mid-2027.</p><h2 class="st-heading-2">How Did KYTX Retail Traders React?</h2><p>On Stocktwits, retail sentiment around KYTX stock jumped from ‘neutral’ to ‘extremely bullish’ over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.</p><p>A Stocktwits user said the stock is a “bargain” at current prices.</p><p><stembedurl>https://stocktwits.com/bioisrisky/message/665023399</stembedurl></p><p>“Very interesting platform is the durability holds up,” another said about the trial results.</p><p><stembedurl>https://stocktwits.com/MarketDegenerate/message/665017160</stembedurl></p><p><a href="https://stocktwits.com/symbol/KYTX">KYTX stock</a> has fallen 26% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/a-55-b-vanguard-bond-fund-manager-says-no-time-to-be-a-hero-as-treasury-yields-spike-across-the-curve/cZMJJSKRB9A">A $55B Vanguard Bond Fund Manager Says ‘No Time To Be A Hero’ As Treasury Yields Spike Across The Curve</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

Global stock market chart and trading board - stock photo

Chief executive Warner Biddle said the therapy’s durability “exceeded even our expectations.” 

Feed

News

Sentiment

Earnings

Fundamentals

Info

KYTX Earnings

Historical Earnings